Respiratory Clinical Trials

Statistical methods in respiratory trials

The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.

All respiratory trials

625 results

• Assessment of the Effect of PAP on Energy and Vitality in Mild OSA Patients: The Merge Study: Complete Statistical AnalysisIndependent statistical analysis of Assessment of the Effect of PAP on Energy and Vitality in Mild OSA Patients: The Merge Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase NAResults postedn = 301NCT02699463
• ASSUREIndependent statistical analysis of Absorption and Safety With Sustained Use of RELiZORB Evaluation (ASSURE) Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase NAResults postedn = 49NCT02750501
• AST-VAC2 Vaccine in Patients With Non-small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of AST-VAC2 Vaccine in Patients With Non-small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03371485).Phase 1Results postedn = 9NCT03371485
• Atezolizumab Immunotherapy in Patients With Advanced NSCLC: Complete Statistical AnalysisIndependent statistical analysis of Atezolizumab Immunotherapy in Patients With Advanced NSCLC: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03102242).Phase 2Results postedn = 64NCT03102242
• Atovaquone and Azithromycin Combination for Confirmed COVID-19 Infection: Complete Statistical AnalysisIndependent statistical analysis of Atovaquone and Azithromycin Combination for Confirmed COVID-19 Infection: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04339426).Phase 2Results postedn = 3NCT04339426
• ATTACCIndependent statistical analysis of ATTACC (NCT04372589), a randomized phase 2/3 trial evaluating antithrombotic therapy with heparin in patients with COVID-19 and pneumonia, including its design, primary endpoint, planned analysis, and statistical interpretation.Phase 2/3n = 1,200NCT04372589
• Auto Continuous Positive Airway Pressure (CPAP) Based Energy Spectrum Analysis of Flow for Treatment of Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS): Complete Statistical AnalysisIndependent statistical analysis of Auto Continuous Positive Airway Pressure (CPAP) Based Energy Spectrum Analysis of Flow for Treatment of Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS): primary endpoint results, effect estimate with confidence…Phase NAResults postedn = 32NCT00750165
• Autologous Stem Cell Treatment for Chronic Lung Disease Study: Complete Statistical AnalysisIndependent statistical analysis of Autologous Stem Cell Treatment for Chronic Lung Disease Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03044431).Phase NAResults postedn = 207NCT03044431
• Avelumab in First-line NSCLC (JAVELIN Lung 100): Complete Statistical AnalysisIndependent statistical analysis of Avelumab in First-line NSCLC (JAVELIN Lung 100): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02576574).Phase 3Results postedn = 1,214NCT02576574
• AZALEAIndependent statistical analysis of the AZALEA phase 4 randomized trial of Zithromax versus placebo in asthma exacerbations, including trial design, the diary card symptom-score endpoint, planned statistical analysis, and interpretation.Phase 4n = 199NCT01444469
• AZD0530 in Treating Patients With Extensive Stage Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of AZD0530 in Treating Patients With Extensive Stage Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 23NCT00528645
• AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02513563).Phase 2Results postedn = 42NCT02513563
• AZI001Independent statistical analysis of Azithromycin in Bronchiolitis Obliterans Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01009619).Phase 4Results postedn = 83NCT01009619
• AZMATICS: AZithroMycin/Asthma Trial In Community Settings: Complete Statistical AnalysisIndependent statistical analysis of AZMATICS: AZithroMycin/Asthma Trial In Community Settings: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00266851).Phase 3Results postedn = 97NCT00266851
• B-cell Immunity to Influenza (SLVP017)- Year 5, 2013: Complete Statistical AnalysisIndependent statistical analysis of B-cell Immunity to Influenza (SLVP017)- Year 5, 2013: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03020537).Phase 4Results postedn = 8NCT03020537
• Bacille Calmette-Guerin (BCG) Vaccine for Immune Protection Against Infections: Complete Statistical AnalysisIndependent statistical analysis of Bacille Calmette-Guerin (BCG) Vaccine for Immune Protection Against Infections: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04884308).Phase 2Results postedn = 30NCT04884308
• Bacterial Pneumonia Score (BPS) Guided Antibiotic Use in Children With Pneumonia and Pneumococcal Vaccine: Complete Statistical AnalysisIndependent statistical analysis of Bacterial Pneumonia Score (BPS) Guided Antibiotic Use in Children With Pneumonia and Pneumococcal Vaccine: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase NAResults postedn = 66NCT01875731
• Balance Function in Patients Post Corona Virus Disease 2019 (COVID-19): Complete Statistical AnalysisIndependent statistical analysis of Balance Function in Patients Post Corona Virus Disease 2019 (COVID-19): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04914364).Phase NAResults postedn = 28NCT04914364
• Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension – CATALYST: Complete Statistical AnalysisIndependent statistical analysis of Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension - CATALYST: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 3Results postedn = 202NCT02657356
• BARI-COVIDAn independent statistical analysis of the BARI-COVID phase 2/3 study of baricitinib in symptomatic patients infected by COVID-19, including its crossover design, ICU-transfer endpoint, planned analysis, and statistical interpretation.Phase 2/3n = 200NCT04320277
• Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations: Complete Statistical AnalysisIndependent statistical analysis of Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2Results postedn = 217NCT04579380
• BATIndependent statistical analysis of the BAT phase 3 trial evaluating prolonged azithromycin treatment in patients with bronchiectasis, including trial design, endpoints, methodology, and interpretation.Phase 3n = 72NCT00415350
• BATTLE Program: Erlotinib in Previously Treated Subjects With Advanced NSCLC: Complete Statistical AnalysisIndependent statistical analysis of BATTLE Program: Erlotinib in Previously Treated Subjects With Advanced NSCLC: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00410059).Phase 2Results postedn = 59NCT00410059
• BEACONAn independent statistical analysis of the randomized phase 3 BEACON trial evaluating QVA149 against concurrent QAB149 plus NVA237 in patients with chronic obstructive pulmonary disease, including its mixed-model FEV1 endpoint and study…Phase 3Results postedn = 193NCT01529632
• BEACONIndependent statistical analysis of Comparison of Safety and Efficacy of the Combination Product QVA149A Against the Concurrent Administration of the Individual Components, QAB149 and NVA237, in Patients With Chronic Obstructive Pulmonary Disease…Phase 3Results postedn = 193NCT01529632
• Beta-blockers in Pulmonary Arterial Hypertension: Complete Statistical AnalysisIndependent statistical analysis of Beta-blockers in Pulmonary Arterial Hypertension: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02507011).Phase 2Results postedn = 2NCT02507011
• BIBW 2992 and BSC Versus Placebo and BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1): Complete Statistical AnalysisIndependent statistical analysis of BIBW 2992 and BSC Versus Placebo and BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1): primary endpoint results, effect estimate with confidence interval,…Phase 3Results postedn = 585NCT00656136
• BinaxNOW for Evaluating Children for Infection With SARS-CoV-2 (COVID-19): Complete Statistical AnalysisIndependent statistical analysis of BinaxNOW for Evaluating Children for Infection With SARS-CoV-2 (COVID-19): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05087524).Phase NAResults postedn = 65NCT05087524
• BioCSI-2Independent statistical analysis of Biomarkers of Cockroach Sublingual Immunotherapy 2: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01380327).Phase 1/2Results postedn = 99NCT01380327
• BIRCHIndependent statistical analysis of A Study of Atezolizumab in Participants With Programmed Death - Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer: primary endpoint results, effect estimate with…Phase 2Results postedn = 667NCT02031458
• Biweekly Schedule of Docetaxel and Cisplatin in High Risk Patients With Unresectable Non-small Cell Lung Cancer (NSCLC): Complete Statistical AnalysisIndependent statistical analysis of Biweekly Schedule of Docetaxel and Cisplatin in High Risk Patients With Unresectable Non-small Cell Lung Cancer (NSCLC): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 2Results postedn = 48NCT00995761
• BLAZE-2Complete statistical analysis of BLAZE-2, a randomized phase 3 trial evaluating bamlanivimab for prevention of COVID-19 in nursing home residents and staff, including trial design, endpoints, logistic regression methodology, reported results, and…Phase 3Results postedn = 1,180NCT04497987
• Bomedemstat and Maintenance Immunotherapy for Treatment of Newly Diagnosed Extensive Stage Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Bomedemstat and Maintenance Immunotherapy for Treatment of Newly Diagnosed Extensive Stage Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 1/2Results postedn = 3NCT05191797
• Booster Dose Trial: Complete Statistical AnalysisIndependent statistical analysis of Booster Dose Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05016622).Phase 2Results postedn = 106NCT05016622
• BOREASAn independent statistical analysis of the phase 3 BOREAS trial of dupilumab versus placebo in COPD with type 2 inflammation, covering the negative binomial exacerbation analysis, MMRM lung-function and symptom endpoints, logistic…Phase 3Results postedn = 939NCT03930732
• BOREASIndependent statistical analysis of Crossover Trial to Assess Efficacy and Safety of Inhaled AQ001S Compared to a Budesonide Suspension in Mild Asthmatics: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 1/2Results postedn = 23NCT04933383
• Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2Results postedn = 42NCT00118144
• BOSTON-4Independent statistical analysis of A Safety Study of Liposomal Cyclosporine A to Treat Bronchiolitis After Hematopoietic Transplant (BOSTON-4): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 6NCT04107675
• BREATHE-1Independent statistical analysis of BREATHE-1, a first-in-human single-group study of the Apreo Implant for severe emphysema or COPD, including its design, primary safety endpoint, planned statistical analysis, and interpretation.Phase NAn = 48NCT05854550
• BREEZEIndependent statistical analysis of the BREEZE phase 1 study of Treprostinil Inhalation Powder in subjects with pulmonary arterial hypertension currently using Tyvaso, including study design, endpoints, planned statistical methods, safety, and interpretation.Phase 1Results postedn = 51NCT03950739
• Brigatinib Before Brain Irradiation Trial (B3i Trial): Complete Statistical AnalysisIndependent statistical analysis of Brigatinib Before Brain Irradiation Trial (B3i Trial): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04634110).Phase 2Results postedn = 1NCT04634110
• Bubble PEP Training Among Patient With Chronic Obstructive Pulmonary Disease in Pulmonary Function Effects: Complete Statistical AnalysisIndependent statistical analysis of Bubble PEP Training Among Patient With Chronic Obstructive Pulmonary Disease in Pulmonary Function Effects: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase NAResults postedn = 57NCT04828837
• BudERIndependent statistical analysis of Effect of Nebulized Budesonide and Oral Corticosteroids on Wheezing Episode Relapse in Children: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 4Results postedn = 61NCT00189436
• Buparid/PARI SINUS Versus Budes® Nasal Spray in the Therapy of Chronic Rhinosinusitis: Complete Statistical AnalysisIndependent statistical analysis of Buparid/PARI SINUS Versus Budes® Nasal Spray in the Therapy of Chronic Rhinosinusitis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 1/2Results postedn = 19NCT01955980
• C3Independent statistical analysis of Community Network-driven COVID-19 Testing and Vaccination of Vulnerable Populations in the Central US: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase NAResults postedn = 1,328NCT04743908
• Cabozantinib-S-Malate and Erlotinib Hydrochloride in Treating Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Cabozantinib-S-Malate and Erlotinib Hydrochloride in Treating Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 2Results postedn = 37NCT01866410
• CADENCEIndependent statistical analysis of the CADENCE phase 2 trial of sotatercept for pulmonary hypertension due to HFpEF, covering its randomized design, pulmonary vascular resistance endpoint, planned analysis, and statistical interpretation.Phase 2n = 164NCT04945460
• CALIPSOIndependent statistical analysis of CALIPSO: Calfactant for Acute Lung Injury in Pediatric Stem Cell Transplant and Oncology Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2/3Results postedn = 43NCT00999713
• Can a Nasal Decongestant Test Predict Treatment Outcomes in Seasonal Allergic Rhinitis?: Complete Statistical AnalysisIndependent statistical analysis of Can a Nasal Decongestant Test Predict Treatment Outcomes in Seasonal Allergic Rhinitis?: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase NAResults postedn = 40NCT00618332
• CAN-COVIDIndependent statistical analysis of CAN-COVID, a randomized phase 3 study of canakinumab versus placebo for cytokine release syndrome in participants with COVID-19-induced pneumonia, including its primary binary endpoint, logistic regression, odds ratio,…Phase 3Results postedn = 454NCT04362813

← All therapeutic areas